Pulse Biosciences Presents Promising Data on Cardiac Catheter System for Atrial Fibrillation Treatment

Got story updates? Submit your updates here. ›

Pulse Biosciences, Inc. has announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrated successful treatment of atrial fibrillation in 150 patients, with rapid procedure times and a favorable safety profile.

Why it matters

The nPulse Cardiac Catheter system represents a potential new treatment option for patients with atrial fibrillation, a common and often chronic heart rhythm disorder. The positive results from this initial feasibility study suggest the technology could offer an effective and safe alternative to existing ablation procedures.

The details

Key findings from the study include a 100% procedural success rate at 6 months and 96% at one year, with an average of 16.1 applications per procedure. Total procedure and fluoroscopy times were 65 and 9.8 minutes, respectively, and the left atrial dwell time was 21.0 minutes. The safety profile was also favorable, with only 1.3% of subjects experiencing a serious adverse event related to the primary safety endpoint.

• The nPulse Cardiac Catheter first-in-human feasibility study is ongoing (NCT06696170).
• The initial cohort of treated patients has been evaluated by remapping at 3 months and for rhythm control completed at 6 and 12 months post ablation procedure.
• The data were presented at the 31st Annual AF Symposium 2026 meeting, taking place February 5-7, 2026, in Boston, MA.